Triple-Drug cocktail shows promise in early prostate cancer trial
NCT ID NCT04477512
First seen Nov 12, 2025 · Last updated May 14, 2026 · Updated 28 times
Summary
This early-phase study tested a combination of three drugs (cabozantinib, abiraterone, and nivolumab) alongside standard hormone therapy in 18 men with metastatic prostate cancer that still responds to hormone treatment. The main goal was to find a safe dose and check for side effects. Researchers also looked at how well the treatment controlled the cancer, such as lowering PSA levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE REFRACTORY PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.